Company Overview

T-NanoBio Therapeutics, Inc., a Delaware corporation, is an emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Our nano immuno-engager ("NIE") platform can harness a patient's own immune system against cancer, while our HER2+ platform will offer a new treatment paradigm for treating HER2+ tumors. The company has sufficient data to progress into pharma/tox studies within 12 months of funding, followed by an IND filing ~~which is expected to be~~ within 20 months. The Company is comprised of a very senior and seasoned team with expertise in ~~all areas of~~ science, clinical development, finance, business, commercialization, CMC and corporate development with over 120 years of combined experience.

Platform Highlights

- Demonstrated conversion of 'cold' to 'hot' tumors in a syngeneic mouse cancer model, creating the ideal clinical setting for immune checkpoint inhibitors.
- In combination with anti-PD-1 antibody, the therapy was able to cure lung and breast cancer bearing mice, resulting in 100% overall survival ~~in mice~~.
- Induced immune memory response against future implantation of breast cancer cells.
- HER2+ targeted transformable nanoparticles as a monotherapy have demonstrated curing HER2+ breast cancer in mice.
- Exclusively licensing technology from the University of California Davis Cancer Center.

How does the Nano Immuno-Engager ("NIE") work in Cancer Immunotherapy?



1) NIE delivered to the tumor
2) NIE transformed to nanofibrils at the tumor cell membrane
3) Nanofibril network at the TME captures T_{eff} cells
4) Allows sustained release of an immunostimulant



Our Technology Differentiation:

Transformation of Nanoparticles into a Nanofibril Network

Creating a nanofibril network that binds to the cancer cells within the Tumor Micro-Environment that:

- Prolongs retention of the immunostimulant
- Captures immune cells
- Activates the immune system
- Spares normal tissues and organs

Nanoparticles





Nanofibril Network



Pipeline: Advancing Transformable Peptide Nanoparticle Programs

Product	Indication	Discovery	IND-enabling	Clinical
NIE	NSCLC, Melanoma, Breast, HNSCC			
HER2+	Solid HER2+ (Breast, Gastric)			
Combination (NIE and HER2+)	Solid HER2+ Tumors			

Leadership

Anthony E. Maida III, PhD
Co-Founder, Chief Executive Officer

Kit S. Lam, MD, PhD
Co-Founder, Chair of Scientific Advisory Board

Robert H. Pierce, MD
Chief Medical Officer

Scientific and Clinical Advisors

o Kit S. Lam, MD, PhD (Chair)

o David Gandara, MD o Jose Lutzky, MD

o Jerome Galon, PhD o Kim Margolin, MD

o Primo Lara, MD o James Talmadge, PhD

Board Members

o Anthony E. Maida III PhD (Chair) o William Ashton o Kit S. Lam, MD, PhD

o Richard B. Slansky, MBA o Bernice Welles, MD

T-NanoBio THERAPEUTICS

Investor & Company Contact:
BD@T-NanoBio.com